Physician profile
Jacqueline Lichtenstein
NPI 1679897060
$2,986.04
in general payments reported to CMS, 2019-2025
15 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $763 · 2023: $526 · 2024: $918 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $859.80 | 2023-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Relievant Medsystems, INC. | $839.89 | 2021-2023 | Intracept |
| Abbott Laboratories | $414.50 | 2021-2025 | Proclaim |
| Collegium Pharmaceutical, INC. | $327.90 | 2021-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $206.30 | 2021-2025 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $56.27 | 2025 | |
| Spinal Simplicity, LLC | $49.38 | 2025 | Ha Minuteman G3-R |
| Arbor Pharmaceuticals, INC. | $45.42 | 2021 | |
| Biotronik Nro, INC. | $45.32 | 2025 | Prospera |
| Kowa Pharmaceuticals America, INC. | $29.64 | 2022 | |
| Abbvie INC. | $28.84 | 2024 | |
| Nevro Corp. | $25.27 | 2023 | Senza |
| Biodelivery Sciences International, INC. | $19.77 | 2021 | |
| Medtronic, INC. | $19.63 | 2024 | Vanta Adaptivestim |
| Ibsa Pharma INC. | $18.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.